On quartery conference call management said May was looking like 0.039 per share. No reason to believe things got worse. In fact, suprise maybe 0.05 per month by 4th quarter.
It's because Chinese imports are not declining as fast as projected. June AKS guidance critical to next AKS share price rally. Merrill won't stick with $9 price target much longer if they don't see AKS improving . GL
Adjusted earnings excluding non-recurring gains were 27 cents per share. Source: earnings release and AP. Nobody is "dumb" when it comes to MREITS they are governed by complex rules. GL
Just remember neither analysts or economists have a clue as to the direction of the economy. It was predicted over and over again in 2014 that interest rates would go up, instead they went down. Also, name one analyst, or economist who predicted that oil would lose 50% of it's value. Zero, nada, zip. Best bet is to look at the customers of AKS. Auto sales are booming, and home construction and remodling are gaining traction. So will AKS. $8.00 to $9.00 is likely this year. Just sayin.
Just enjoy the money you have made. If you read the press release written by the lawyers (Skadden Arps) you will find all of the correct due diligence verbage. The target price is more than 20% higher than the day earlier closing price, and more than 35% higher than the past 90 day average price. I'm sure all the avidavits are in place which shows a range in value for SIMG from the investment banking community with $7.30 on the high side. These legal reviews seldom result in lawsuits and if suits it's even more rare that they result in eventual success. We are dealing with a small value take over of hardly more than 1/2 billion dollars being represented by one of the best and oldest M & A law firms in the U. S. (Skadden Arps) . So either sell your shares now to the arbs or wait for your check. Either way you win.
let's do the CPR math. I am going to use averages for the sake of illustration, in real life CPR's are built from the pool level up. Having said that the averages can provide valuable insight into any portfolio. So the annualized CPR was 8.7% times the portfolio balance of $15,421.9 billion equals( rounded) to $1,342 billion in payoffs over the next 12 months. The weighted average purchase price is 105.5% (5.5% over par) times $1,342 billion equals $73.81 million divided by 12 equals a projected $6.15 million premium write off per month. In addition, the $1,342 billion run down in portfolio means gross income is reduced by $1.342 billion times weighted average net coupon of 3.47& or $46.57 million (gross) or $3.88 million per month. . So the total effect of the CPR is about $10.0 million per month or less than 2%of total gross income. .Very manageable. So after expensing repo interest and monthly hedge cost (based on past experience) should lead to the strong possibility of returning to a 15 cents quarterly dividend in the coming quarters. See you next month.
Excellent update. they have expanded the portfolio and if you do the math with around a 1.40 spread they can easily support a return to a 15 cent quarterly dividend. CPR rates behaved better than expected and with the Daragi QE program boosting interest rates (our 10 yr treasury at 1.94% vs 1.70% last week) refinance pressures may begin to ebb. I'm adding to my position starting today. GLTA
Wow at 8.7% for the portfolio much lower than one would expect. The last time rates were this low the CPR was 13% to 16%. the 15 year portfolio is showing it's true colors and will help protect Book Value. GL.
Don't worry Barclays is doing the thinking for you. Most likely already had a buyer when they approached SIMG, Now it's just a matter of price so the SIMG Board doesn't get sued for selling too cheaply. Gotta love the nactivist investors they undoubtedly were behind putting SIMG in play. $8 to $9 a share not impossible because no debt and an easy all cash deal for $700 million or less. Should be cashing our checks soon!!
The market in my opinion is currently not pricing in lower commodity costs for lumber or copper. My bet is margins will improve as the year progresses. I think you will be proved wrong at $8 in the next 12 months. With low interest rates, the FHA reducing insurance premiums so sellers can more easily sell and move up to a SPF home the future is bright and much more likely a $9 handle than $8.00. It's hard to believe Mr. Market is leaving so much money on the table for SPR and I would expect more stock upgrades in the months ahead.
Yes, one of the reasons ARR went from a 30 year portfolio to a 15 year portfolio was to reduce interest rate risk and protect book value. Hedges limit interest rate risk by paying off in a rising or falling interest rate environment depending on what future interest rate move you are trying to limit from an adverse financial impact. Please note ARR amortization of premiums is expensed monthly as it occurs, no yield smoothing techniques are used. This is admirable transparency but can cause larger monthly write offs as CPR's increase. Once again, my theory/guess is that history will repeat itself and ARR is better protected from premium write downsthen the market is pricing in. ARR is currently a buy in my book at these levels. Let's watch those CPR's later today.
Everyone knows this is all about CPR's and how much of the portfolio will be refinanced away with accompaning write downs of the purchase premiums. The dirty little secret is 15 year paper is not as likely to be refinanced as 30 year paper because the shorter term gives the mortgagor less bang for the buck than 30 year refinances. BV is much more likely to go up than down due to the year end 10 year treasury being at 2.17%. Watch the CPR in the company update today which will be the tell.
I have a small position in EXEL and thinking of adding more.I know the prostate cancer trial was a failure for extending survival rates (or it did a little better than prednisone) but I believe a trial regarding prostate cancer pain will be wrapping up soon. Is it possible if the trail releives pain statistically better than other drugs that there could still be a way forward for cabozantinib since it did perform marginally better in survival rate than prednisone alone? Thanks for your opinions.
I was thinking of doing the same but looking for double to 50 cents. Unbelievable how much money has been made in this stock in the last 2 weeks. For me sell now and buy the 3 series BMW or be a little more greedy and go for the 7'series and hoping I don't end up with a used VW bug!